deferoxamine has been researched along with Dysmyelopoietic Syndromes in 39 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The study evaluated the cost effectiveness of deferasirox (Exjade * ) compared to non-proprietary desferrioxamine (DFO) for the control of transfusional iron overload in lower risk myelodysplastic syndromes (MDS) patients." | 7.76 | Cost effectiveness of deferasirox compared to desferrioxamine in the treatment of iron overload in lower-risk, transfusion-dependent myelodysplastic syndrome patients. ( Bozkaya, D; Li, Q; Migliaccio-Walle, K; Miranda, E; Oliver, N; Tolley, K, 2010) |
| "To verify efficacy and tolerability of deferoxamine by subcutaneous bolus injection as compared to the conventional pump-driven slow infusion, eleven patients affected by oncohematologic diseases were given 2 g of deferoxamine diluted in 10 mL of distilled water over twelve hours by continuous infusion, or by bolus injection in two divided doses." | 7.70 | Subcutaneous bolus injection of deferoxamine in adult patients affected by onco-hematologic diseases and iron overload. ( Aprili, G; Borgna-Pignatti, C; De Gironcoli, M; Franchini, M; Gandini, G; Vassanelli, A, 1998) |
| "A number of studies have shown that regular chelation therapy with deferoxamine is effective in patients with secondary hemochromatosis." | 7.69 | [Long-term efficacy of subcutaneous administration of deferoxamine in patients with secondary hemochromatosis]. ( Fujisawa, S; Kobayashi, M; Yano, K, 1996) |
| " Despite the availability of deferoxamine (DFO) in Korea since 1998, data from patients with myelodysplastic syndromes, aplastic anemia, and other BMFS show significant iron overload and damage to the heart and liver." | 4.84 | Iron chelation therapy in the myelodysplastic syndromes and aplastic anemia: a review of experience in South Korea. ( Lee, JW, 2008) |
| " In July 1996, deferoxamine was administered for iron overload." | 4.80 | [Development of arterial thrombus of Mucorales hyphae during deferoxamine therapy in a patient with aplastic anemia in transformation to myelodysplastic syndrome]. ( Kajiguchi, T; Miyata, Y; Saito, M; Takeyama, H, 2000) |
| "The main objective of the study was to analyze the incidence of iron overload (IO) and its management in transfusion-dependent patients with low-risk myelodysplastic syndrome (MDS) before the license of deferasirox." | 3.76 | Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements. ( Arrizabalaga, B; Del Cañizo, C; Remacha, AF; Sanz, G; Villegas, A, 2010) |
| "The study evaluated the cost effectiveness of deferasirox (Exjade * ) compared to non-proprietary desferrioxamine (DFO) for the control of transfusional iron overload in lower risk myelodysplastic syndromes (MDS) patients." | 3.76 | Cost effectiveness of deferasirox compared to desferrioxamine in the treatment of iron overload in lower-risk, transfusion-dependent myelodysplastic syndrome patients. ( Bozkaya, D; Li, Q; Migliaccio-Walle, K; Miranda, E; Oliver, N; Tolley, K, 2010) |
| " Recombinant erythropoietin alfa and darbepoetin alfa have been the mainstay of therapy for treating anemia associated with MDS." | 3.74 | The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines. ( Cosler, LE; Ferro, SA; Greenberg, PL; Lyman, GH, 2008) |
| "To verify efficacy and tolerability of deferoxamine by subcutaneous bolus injection as compared to the conventional pump-driven slow infusion, eleven patients affected by oncohematologic diseases were given 2 g of deferoxamine diluted in 10 mL of distilled water over twelve hours by continuous infusion, or by bolus injection in two divided doses." | 3.70 | Subcutaneous bolus injection of deferoxamine in adult patients affected by onco-hematologic diseases and iron overload. ( Aprili, G; Borgna-Pignatti, C; De Gironcoli, M; Franchini, M; Gandini, G; Vassanelli, A, 1998) |
| "A number of studies have shown that regular chelation therapy with deferoxamine is effective in patients with secondary hemochromatosis." | 3.69 | [Long-term efficacy of subcutaneous administration of deferoxamine in patients with secondary hemochromatosis]. ( Fujisawa, S; Kobayashi, M; Yano, K, 1996) |
| "Iron overload is characterized by excessive iron deposition and consequent injury and dysfunction of the heart, liver, anterior pituitary, pancreas, and joints." | 2.44 | Chelation therapy for iron overload. ( Barton, JC, 2007) |
| "Myelodysplastic syndromes (MDS) and aplastic anemia (AA) are the most common anemias that require transfusion therapy in Japan." | 1.34 | Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. ( Harada, M; Kanakura, Y; Murate, T; Nakahata, T; Nakao, S; Okamoto, S; Ozawa, K; Sawada, K; Takatoku, M; Tomonaga, M; Uchiyama, T, 2007) |
| "In acute B19 parvovirus infections an underlying hematologic disease should be excluded." | 1.31 | [An older female patient with refractory anemia and hemochromatosis]. ( Ceconi, C; Fabel, H; Flemming, P; Schuppert, F; Sutor, GC; Wysk, J, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.56) | 18.7374 |
| 1990's | 8 (20.51) | 18.2507 |
| 2000's | 12 (30.77) | 29.6817 |
| 2010's | 18 (46.15) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wong, SA | 1 |
| Leitch, HA | 3 |
| Gattermann, N | 2 |
| Zheng, Q | 1 |
| Zhao, Y | 1 |
| Guo, J | 1 |
| Zhao, S | 1 |
| Fei, C | 1 |
| Xiao, C | 1 |
| Wu, D | 1 |
| Wu, L | 1 |
| Li, X | 1 |
| Chang, C | 1 |
| Taher, AT | 1 |
| Origa, R | 1 |
| Perrotta, S | 1 |
| Kouraklis, A | 1 |
| Ruffo, GB | 1 |
| Kattamis, A | 1 |
| Goh, AS | 1 |
| Huang, V | 1 |
| Zia, A | 1 |
| Herranz, RM | 1 |
| Porter, JB | 1 |
| Ghosh, K | 2 |
| Merkel, DG | 1 |
| Nagler, A | 1 |
| Banerjee, A | 1 |
| Mifsud, NA | 1 |
| Bird, R | 1 |
| Forsyth, C | 1 |
| Szer, J | 1 |
| Tam, C | 1 |
| Kellner, S | 1 |
| Grigg, A | 1 |
| Motum, P | 1 |
| Bentley, M | 1 |
| Opat, S | 1 |
| Grigoriadis, G | 1 |
| Cerchione, C | 1 |
| Cerciello, G | 1 |
| Avilia, S | 1 |
| Della Pepa, R | 1 |
| Pugliese, N | 1 |
| Picardi, M | 1 |
| Catalano, L | 1 |
| Pane, F | 1 |
| Lee, JW | 1 |
| Greenberg, PL | 2 |
| Cosler, LE | 1 |
| Ferro, SA | 1 |
| Lyman, GH | 1 |
| Remacha, AF | 1 |
| Arrizabalaga, B | 2 |
| Del Cañizo, C | 2 |
| Sanz, G | 1 |
| Villegas, A | 2 |
| Vickars, LM | 1 |
| Rose, C | 2 |
| Brechignac, S | 1 |
| Vassilief, D | 1 |
| Pascal, L | 1 |
| Stamatoullas, A | 1 |
| Guerci, A | 1 |
| Larbaa, D | 1 |
| Dreyfus, F | 1 |
| Beyne-Rauzy, O | 1 |
| Chaury, MP | 1 |
| Roy, L | 1 |
| Cheze, S | 1 |
| Morel, P | 1 |
| Fenaux, P | 2 |
| Fausel, CA | 1 |
| Tolley, K | 1 |
| Oliver, N | 1 |
| Miranda, E | 1 |
| Migliaccio-Walle, K | 1 |
| Bozkaya, D | 1 |
| Li, Q | 1 |
| López Arrieta, JM | 1 |
| De Paz, R | 1 |
| Altés, A | 1 |
| Armand, P | 1 |
| Sainvil, MM | 1 |
| Kim, HT | 1 |
| Rhodes, J | 1 |
| Cutler, C | 1 |
| Ho, VT | 1 |
| Koreth, J | 1 |
| Alyea, EP | 1 |
| Neufeld, EJ | 1 |
| Kwong, RY | 1 |
| Soiffer, RJ | 1 |
| Antin, JH | 1 |
| Shah, J | 1 |
| Kurtin, SE | 1 |
| Arnold, L | 1 |
| Lindroos-Kolqvist, P | 1 |
| Tinsley, S | 1 |
| Ruivard, M | 1 |
| Wang, XJ | 1 |
| Yin, QS | 1 |
| Wei, XD | 1 |
| Sutor, GC | 1 |
| Ceconi, C | 1 |
| Flemming, P | 1 |
| Wysk, J | 1 |
| Fabel, H | 1 |
| Schuppert, F | 1 |
| Kubota, N | 1 |
| Miyazawa, K | 1 |
| Shoji, N | 1 |
| Sumi, M | 1 |
| Nakajima, A | 1 |
| Kimura, Y | 1 |
| Oshiro, H | 1 |
| Ebihara, Y | 1 |
| Ohyashiki, K | 1 |
| González, FA | 1 |
| Alonso, D | 1 |
| Castro, M | 1 |
| Remacha, A | 1 |
| del Arco, A | 1 |
| Martín Núñez, G | 1 |
| Barton, JC | 1 |
| Takatoku, M | 1 |
| Uchiyama, T | 1 |
| Okamoto, S | 1 |
| Kanakura, Y | 1 |
| Sawada, K | 1 |
| Tomonaga, M | 1 |
| Nakao, S | 1 |
| Nakahata, T | 1 |
| Harada, M | 1 |
| Murate, T | 1 |
| Ozawa, K | 1 |
| Ghoti, H | 1 |
| Amer, J | 1 |
| Winder, A | 1 |
| Rachmilewitz, E | 1 |
| Fibach, E | 1 |
| Lewinski, UH | 1 |
| Floru, S | 1 |
| Cohen, AM | 1 |
| Mittelmann, M | 1 |
| Levina, AA | 1 |
| Tsvetaeva, NV | 1 |
| Minaeva, LM | 1 |
| Tsibul'skaia, MM | 1 |
| Shcherbinina, SP | 1 |
| Zavadenko, MA | 1 |
| Meshcheriakova, LM | 1 |
| Tokarev, IuN | 1 |
| Jensen, PD | 2 |
| Heickendorff, L | 1 |
| Pedersen, B | 1 |
| Bendix-Hansen, K | 1 |
| Jensen, FT | 1 |
| Christensen, T | 1 |
| Boesen, AM | 1 |
| Ellegaard, J | 2 |
| Kobayashi, M | 1 |
| Yano, K | 1 |
| Fujisawa, S | 1 |
| Aul, C | 1 |
| Jaeger, M | 1 |
| Borgna-Pignatti, C | 1 |
| Franchini, M | 1 |
| Gandini, G | 1 |
| Vassanelli, A | 1 |
| De Gironcoli, M | 1 |
| Aprili, G | 1 |
| Miyata, Y | 1 |
| Kajiguchi, T | 1 |
| Saito, M | 1 |
| Takeyama, H | 1 |
| Cambier, N | 1 |
| Mahieu, M | 1 |
| Ernst, O | 1 |
| Jensen, IM | 1 |
| Marsh, JH | 1 |
| Hundert, M | 1 |
| Schulman, P | 1 |
| Daly, AL | 1 |
| Velazquez, LA | 1 |
| Bradley, SF | 1 |
| Kauffman, CA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)[NCT02125877] | Phase 2 | 173 participants (Actual) | Interventional | 2014-07-08 | Completed | ||
| A Pilot Study of Deferoxamine Before and During Myeloablative Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndromes or Acute Leukemia and Iron Overload[NCT00658411] | 5 participants (Actual) | Interventional | 2008-08-31 | Terminated (stopped due to Closed due to slow patient accrual) | |||
| A Trial of Oral Nifedipine for the Treatment of Iron Overload[NCT00712738] | Phase 1 | 6 participants (Actual) | Interventional | 2008-06-20 | Completed | ||
| The Effect of Treatment With the Oral Iron Chelator Deferiprone on the Oxidative Stress of Blood Cells and on Iron Overload Status in Transfusion Dependent, Iron-overloaded Patients With Low Risk Myelodysplastic Syndrome[NCT02477631] | Phase 2 | 19 participants (Actual) | Interventional | 2016-02-29 | Completed | ||
| Kinetics of the Plasmatic Concentration of L-Ascorbic Acid in Patient With Myelodysplastic Syndromes and Control Subjects[NCT02809222] | 138 participants (Actual) | Interventional | 2016-10-25 | Completed | |||
| Open Label, Multicenter Study to Evaluate Safety/Tolerability and Efficacy of Deferasirox (ICL670) in Myelodysplastic Syndrome Patients With Chronic Transfusional Hemosiderosis.[NCT00469560] | Phase 3 | 158 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Blood samples were collected to assess AUClast. (NCT02125877)
Timeframe: week 1, day 1: pre-dose (0 hour) and 1, 2, 3, 4, 8 and 24 hours post dose; week 3, day 1: pre-dose (0 hour) and 1, 2, 3, 4, 8 and 24 hours post dose
| Intervention | umol/L*h (Mean) | |
|---|---|---|
| week1 (n=14,15) | week 3 (n=13,15) | |
| Deferasirox Dispersible Tablet (DFX-DT) | 1110 | 1590 |
| Deferasirox Film-coated Tablet (DFX-FCT) | 1040 | 2110 |
Blood samples were collected to assess deferasirox concentration. Dose-adjusted calculations are presented: (concentration/actual dose)*20 for participants on DFX-DT and (concentration/actual dose)*14 for participants on DFX-FCT. (NCT02125877)
Timeframe: Week 3, day 1, pre-dose (0 hour (h)) and 2 h post-dose; week 13, day 1, pre-dose (0 hour (h)) and 2 h post-dose; and week 21, day 1, pre-dose (0 hour (h)) and 2 h post-dose
| Intervention | umol/L (Mean) | |||||
|---|---|---|---|---|---|---|
| week 3, pre-dose (n=63,70) | week 3, 2 hours post-dose (n=67,76) | week 13, pre-dose (n=69.56) | week 13, 2 hours post-dose (n=74,59) | week 21, pre-dose (n=54,59) | week 21, 2 hours post-dose (n=59,64) | |
| Deferasirox Dispersible Tablet (DFX-DT) | 39.6 | 80.8 | 37.1 | 78.7 | 46.6 | 89.8 |
| Deferasirox Film-coated Tablet (DFX-FCT) | 27.3 | 95.5 | 31.3 | 92.5 | 43.1 | 105 |
The percentage of participants with any GI adverse event, diarrhea, constipation, nausea, vomiting, abdominal pain was assessed. (NCT02125877)
Timeframe: 28 weeks
| Intervention | Percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Any GI adverse event | Abdominal pain | Constipation | Diarrhea | Nausea | Vomiting | |
| Deferasirox Dispersible Tablet (DFX-DT) | 61.6 | 26.7 | 15.1 | 34.9 | 26.7 | 22.1 |
| Deferasirox Film-coated Tablet (DFX-FCT) | 58.6 | 26.4 | 8.0 | 33.3 | 27.6 | 17.2 |
The modified SICT consisted of 13 items that represent 3 domains: adherence, satisfaction and concerns. The adherence domain consisted of 7 items, 6 which were measured using a 5-point response scale and was calculated by summing the 6 items. The score range from 6 to 30 and higher scores indicated worse adherence. The satisfaction domain consisted of 3 items, 2 which were measured using a 5-point response scale and was calculated by summing the 2 items. The score range from 2 to 10 and higher scores indicated worse satisfaction. The concerns domain consisted of 3 items to address any concerns or worries with his/her medication. All 3 items were measured on a 5-point response scale and were calculated by summing the 3 items. The score range from 3 to 15 and higher scores indicated fewer concerns. For all three domains, the meaningful difference between two treatment arms was determined to be 1 point. (NCT02125877)
Timeframe: weeks 2, 3, 13 and 24 (end of treatment or within 7 days of last dose)
| Intervention | score on a scale (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| week 2, adherence (n=70,70) | week 2, satisfaction/preference (n=70,70) | week 2, concerns (n=70,70) | week 3, adherence (n=58,51) | week 3, satisfaction/preference (n=58,51) | week 3, concerns (n=58,51) | week 13, adherence (n=59,64) | week 13, satisfaction/preference (n=59,64) | week 13, concerns (n=59,64) | week 24, adherence (n=63,60) | week 24, satisfaction/preference (n=63,60) | week 24, concerns (n=63,60) | |
| Deferasirox Dispersible Tablet (DFX-DT) | 10.3 | 5.2 | 12.9 | 10.9 | 5.4 | 12.4 | 11.2 | 5.4 | 12.7 | 12.5 | 5.8 | 11.8 |
| Deferasirox Film-coated Tablet (DFX-FCT) | 7.6 | 2.8 | 13.8 | 7.7 | 2.6 | 14.0 | 7.8 | 2.9 | 13.6 | 7.5 | 2.9 | 13.7 |
A compliance questionnaire assessed whether the medication was taken. Weekly average compliance was calculated when there were at least four non-missing daily responses. (NCT02125877)
Timeframe: Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
| Intervention | Participants (Number) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| week 1 | week 2 | week 3 | week 4 | week 5 | week 6 | week 7 | week 8 | week 9 | week 10 | week 11 | week 12 | week 13 | week 14 | week 15 | week 16 | week 17 | week 18 | week 19 | week 20 | week 21 | week 22 | week 23 | week 24 | |
| Deferasirox Dispersible Tablet (DFX-DT) | 56 | 64 | 62 | 58 | 56 | 62 | 55 | 56 | 53 | 52 | 50 | 50 | 49 | 51 | 48 | 48 | 43 | 43 | 40 | 40 | 39 | 38 | 36 | 30 |
| Deferasirox Film-coated Tablet (DFX-FCT) | 53 | 64 | 56 | 58 | 58 | 51 | 48 | 46 | 45 | 46 | 42 | 41 | 47 | 42 | 42 | 40 | 39 | 38 | 37 | 36 | 36 | 34 | 33 | 24 |
Blood samples were collected to assess Cmax. (NCT02125877)
Timeframe: week 1, day 1: pre-dose (0 hour) and 1, 2, 3, 4, 8 and 24 hours post dose; week 3, day 1: pre-dose (0 hour) and 1, 2, 3, 4, 8 and 24 hours post dose
| Intervention | umol/L (Mean) | |
|---|---|---|
| week 1 (n=14,15) | week 3 (n=14,15) | |
| Deferasirox Dispersible Tablet (DFX-DT) | 74.6 | 118 |
| Deferasirox Film-coated Tablet (DFX-FCT) | 79.3 | 139 |
The percentage of participants with post-baseline laboratory values meeting specified criteria for notable/extended range was assessed. The following laboratory parameters were measured: platelet count, absolute neutrophils, serum creatinine , creatinine clearance, urinary protein/urinary creatinine ratio, alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Note that within data categories, creat = creatinine, cons = consecutive, ULN = upper limit of normal and urin = urinary. (NCT02125877)
Timeframe: baseline (BL), 30 weeks
| Intervention | Percentage of participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| platelet count, notable range: <100 x 10^9/L | platelet count, extended range: <50 x 10^9/L | absolute neutrophils, notable range: <1.5 x 10^9/L | absolute neut., extended range: <0.5 x 10^9/L | serum creat, 2 cons >33% incr. from BL and >ULN | creat clearance, notable range: 2 cons <60mL/min | creat clearance, extended range: 2 cons <40mL/min | urin protein/urin creat ratio, 2 cons >1.0 mg/mg | ALT, notable range: >5 x ULN and >2 x BL | ALT, extended range: >10 x ULN and >2 x BL | AST, notable range: >5 x ULN and >2 x BL | AST, extended range: >10 x ULN and >2 x BL | |
| Deferasirox Dispersible Tablet (DFX-DT) | 9.3 | 3.5 | 8.1 | 4.7 | 4.7 | 7.0 | 2.3 | 2.3 | 1.2 | 1.2 | 0 | 1.2 |
| Deferasirox Film-coated Tablet (DFX-FCT) | 8.0 | 5.7 | 13.8 | 0 | 3.4 | 2.3 | 2.3 | 0 | 1.1 | 0 | 1.1 | 0 |
The percentage of participants with adverse events, serious adverse events and deaths was assessed. (NCT02125877)
Timeframe: 28 weeks
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| Adverse events | SAEs | Deaths | |
| Deferasirox Dispersible Tablet (DFX-DT) | 89.5 | 15.1 | 0 |
| Deferasirox Film-coated Tablet (DFX-FCT) | 89.7 | 18.4 | 1.1 |
"The palatability questionnaire consisted of 4 items. The first item measured the taste and aftertaste of the medication and were scored a on a 5-point response scale. The second item offered an additional response option of no aftertaste. The last 2 items referred to whether the medication was taken, i.e. swallowed or vomited, and how the participant perceived the amount of medication to be taken. The palatability summary score was calculated using a scoring matrix from items 1, 3 and 4 scores and the score ranges from 0 - 11. Higher scores indicated the best palatability. A meaningful difference between two treatment arms was determined to be 1 point." (NCT02125877)
Timeframe: weeks 2, 3, 13 and 24 (end of treatment or within 7 days of last dose)
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| week 2 (n=69,70) | week 3 (n=57,51) | week 13 (n=59,62) | week 24 (n=63,60) | |
| Deferasirox Dispersible Tablet (DFX-DT) | 9.0 | 8.8 | 9.3 | 8.8 |
| Deferasirox Film-coated Tablet (DFX-FCT) | 10.8 | 10.8 | 10.8 | 10.9 |
Blood samples were collected to assess Tmax. (NCT02125877)
Timeframe: week 1, day 1: pre-dose (0 hour) and 1, 2, 3, 4, 8 and 24 hours post dose; week 3, day 1: pre-dose (0 hour) and 1, 2, 3, 4, 8 and 24 hours post dose
| Intervention | hour (Median) | |
|---|---|---|
| week 1 (n=14,15) | week 3 (n=14,15) | |
| Deferasirox Dispersible Tablet (DFX-DT) | 3.57 | 2.85 |
| Deferasirox Film-coated Tablet (DFX-FCT) | 2.00 | 2.02 |
The GI symptom diary consisted of 6 items, five which were scored using a 0 - 10 rating scale with item appropriate anchors to rate the symptom, for example, Pain in your belly: 0 = no pain and 10 = worst pain. The GI diary summary score was created using the 10 point response scale for the 5 items. The GI symptom daily diary had a minimum score of 0 and a maximum score of 50. The weekly average score for the 7 days was calculated for each individual item and the GI summary score was created from these weekly averages. Higher scores indicated worse symptoms. A meaningful difference between two treatment arms was determined to be 0.3 point. (NCT02125877)
Timeframe: weeks -1, 4, 8, 12, 16, 20, 24
| Intervention | score on a scale (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| week -1 (n=69,65) | week 4 (n=60,64) | week 8 (n=59,51) | week 12 (n=51,45) | week 16 (n=48,41) | week 20 (n40,39) | week 24 (n32,26) | |
| Deferasirox Dispersible Tablet (DFX-DT) | 1.4 | 1.8 | 1.4 | 1.7 | 1.9 | 1.5 | 1.5 |
| Deferasirox Film-coated Tablet (DFX-FCT) | 1.9 | 1.1 | 1.1 | 1.0 | 0.9 | 0.9 | 1.2 |
The dose violation is defined as a dose either missed completely or not taken in accordance with the timing instruction (no later than 12:00 pm. The rate was calculated as [number of dose violations/drug exposure (days)] x 100. (NCT02125877)
Timeframe: weeks 1, 4, 8, 12, 16, 20, 24
| Intervention | percent dose violation (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| week 1 (n=56,53) | week 4 (n=58,58) | week 8 (n=56,46) | week 12 (n=50,41) | week 16 (n=48,40) | week 20 (n=40,36) | week 24 (n=30,24) | |
| Deferasirox Dispersible Tablet (DFX-DT) | 17.7 | 15.8 | 18.0 | 15.7 | 13.5 | 22.6 | 17.1 |
| Deferasirox Film-coated Tablet (DFX-FCT) | 15.8 | 6.7 | 8.4 | 10.7 | 10.0 | 11.3 | 10.1 |
Survival information for the 5 patients who were treated with deferoxamine was collected. This information was used to determine transplant-related mortality, relapse, disease-free and overall survival. (NCT00658411)
Timeframe: 1 year
| Intervention | participants (Number) |
|---|---|
| Transplant-Related Mortality (Deferoxamine) | 0 |
| Relapse (Deferoxamine) | 0 |
| Disease-Free Survival (Deferoxamine) | 5 |
| Overall Survival (Deferoxamine) | 0 |
"All patients meeting the criteria for Severe iron overload as defined by BOTH:~ferritin ≥ 1000 ng/ml and liver iron content(LIC) ≥ 5 mg/gdw were enrolled and received chelation therapy with Deferoxamine. All patients who received chelation therapy were monitored for grade 3 or above toxicity Attributable to Deferoxamine(grades defined by the CTCAE Version 3). The number of participants with grade 3 or higher toxicities were measured and used to determine the safety of chelation therapy." (NCT00658411)
Timeframe: Baseline , 6 month, 1 year
| Intervention | Participants (Number) | ||
|---|---|---|---|
| Baseline | 6 month | 1 year | |
| Deferoxamine | 5 | 0 | 0 |
12 reviews available for deferoxamine and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Iron overload in myelodysplastic syndromes (MDS).
Topics: Benzoates; Blood Transfusion; Deferasirox; Deferoxamine; Erythropoiesis; Hepcidins; Humans; Intestin | 2018 |
Toward resolving the unsettled role of iron chelation therapy in myelodysplastic syndromes.
Topics: Administration, Oral; Benzoates; Blood Transfusion; Chelation Therapy; Deferasirox; Deferiprone; Def | 2014 |
Iron chelation therapy in the myelodysplastic syndromes and aplastic anemia: a review of experience in South Korea.
Topics: Anemia, Aplastic; Deferoxamine; Endocrine System; Female; Humans; Iron; Iron Overload; Korea; Liver; | 2008 |
Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron?
Topics: Aged; Anemia; Benzoates; Blood Component Transfusion; Chelation Therapy; Combined Modality Therapy; | 2009 |
Management of transfusion-related iron overload in patients with myelodysplastic syndromes.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating A | 2012 |
[Iron chelating therapy in adults: How and when ?].
Topics: Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Deferasirox; Deferiprone; Deferoxamine; Humans; Ir | 2013 |
[Deferoxamine-induced interstitial pulmonary injury: a case report and literature review].
Topics: Adult; Deferoxamine; Humans; Lung Diseases, Interstitial; Male; Myelodysplastic Syndromes | 2012 |
Myelodysplastic syndromes: iron overload consequences and current chelating therapies.
Topics: Administration, Oral; Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Erythroc | 2006 |
Chelation therapy for iron overload.
Topics: Anemia; Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferipron | 2007 |
[Development of arterial thrombus of Mucorales hyphae during deferoxamine therapy in a patient with aplastic anemia in transformation to myelodysplastic syndrome].
Topics: Anemia, Aplastic; Chelating Agents; Deferoxamine; Fatal Outcome; Female; Humans; Iron Overload; Midd | 2000 |
[Iron overload and myelodysplastic syndromes].
Topics: Administration, Oral; Aged; Biopsy; Chelation Therapy; Deferiprone; Deferoxamine; Erythrocyte Transf | 2001 |
Mucormycosis: association with deferoxamine therapy.
Topics: Deferoxamine; Drug Overdose; Female; Humans; Iron; Middle Aged; Mucormycosis; Myelodysplastic Syndro | 1989 |
2 trials available for deferoxamine and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Patient-reported outcomes from a randomized phase II study of the deferasirox film-coated tablet in patients with transfusion-dependent anemias.
Topics: Adult; Blood Transfusion; Chelation Therapy; Deferoxamine; Female; Humans; Iron Chelating Agents; Ir | 2018 |
Pre-transplantation iron chelation in patients with MDS or acute leukemia and iron overload undergoing myeloablative allo-SCT.
Topics: Adult; Chelation Therapy; Deferoxamine; Drug Monitoring; Early Termination of Clinical Trials; Feasi | 2013 |
25 other studies available for deferoxamine and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Iron chelation therapy in lower IPSS risk myelodysplastic syndromes; which subtypes benefit?
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine | 2018 |
Iron overload promotes mitochondrial fragmentation in mesenchymal stromal cells from myelodysplastic syndrome patients through activation of the AMPK/MFF/Drp1 pathway.
Topics: Adenosine Triphosphate; AMP-Activated Protein Kinases; Apoptosis; Case-Control Studies; Cell Line; D | 2018 |
Iron chelators or therapeutic modulators of iron overload: Are we anywhere near ideal one?
Topics: Animals; beta-Thalassemia; Chelating Agents; Deferiprone; Deferoxamine; Humans; Hydroxyurea; Iron Ov | 2018 |
The oral iron chelator deferasirox inhibits NF-κB mediated gene expression without impacting on proximal activation: implications for myelodysplasia and aplastic anaemia.
Topics: Anemia, Aplastic; Animals; Benzoates; Bone Marrow Cells; Cell Line; Cells, Cultured; Deferasirox; De | 2015 |
Management of iron overload in myelodysplastic syndromes: combined deferasirox and deferoxamine in a patient with liver disease.
Topics: Deferasirox; Deferoxamine; Hepatitis C; Humans; Hypertension, Portal; Iron Overload; Liver Cirrhosis | 2018 |
The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines.
Topics: Anemia; Antineoplastic Agents; Azacitidine; Cost of Illness; Costs and Cost Analysis; Darbepoetin al | 2008 |
Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements.
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Chelation Therapy; Deferasirox; Deferoxamine; Erythrocyte | 2010 |
Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies).
Topics: Aged; Aged, 80 and over; Chelation Therapy; Comorbidity; Deferoxamine; Disease Progression; Female; | 2010 |
Iron chelation therapy in myelodysplastic syndromes.
Topics: Benzoates; Cost-Benefit Analysis; Deferasirox; Deferiprone; Deferoxamine; Education, Continuing; Hum | 2010 |
Iron chelation therapy in MDS: does it improve survival?
Topics: Chelation Therapy; Deferoxamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Fol | 2010 |
Cost effectiveness of deferasirox compared to desferrioxamine in the treatment of iron overload in lower-risk, transfusion-dependent myelodysplastic syndrome patients.
Topics: Benzoates; Cost-Benefit Analysis; Deferasirox; Deferoxamine; Erythrocyte Transfusion; Humans; Insura | 2010 |
[Myelodysplastic syndrome in the elderly: comprehensive geriatric assessment and therapeutic recommendations].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Blood Transfusion; Decision Support Techniques; Defe | 2012 |
[An older female patient with refractory anemia and hemochromatosis].
Topics: Aged; Anemia, Sideroblastic; Colonic Polyps; Deferoxamine; Diagnosis, Differential; Female; Ferritin | 2002 |
A massive intraventricular thrombosis by disseminated mucormycosis in a patient with myelodysplastic syndrome during deferoxamine therapy.
Topics: Aged; Cerebral Ventricle Neoplasms; Cerebral Ventricles; Deferoxamine; Fatal Outcome; Humans; Male; | 2003 |
[Study of deferoxamine in subcutaneous profusion treatment of iron overload in myelodysplastic syndromes].
Topics: Aged; Anemia, Refractory; Anemia, Sideroblastic; Blood Transfusion; Deferoxamine; Female; Ferritins; | 2005 |
Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Aplastic; Blood Transfusion; Cause of Death; Deferoxamine; F | 2007 |
Oxidative stress in red blood cells, platelets and polymorphonuclear leukocytes from patients with myelodysplastic syndrome.
Topics: Acetylcysteine; Aged; Aged, 80 and over; Antioxidants; Blood Platelets; Chelating Agents; Deferipron | 2007 |
Oxidative stress in red blood cells, platelets and polymorphonuclear leukocytes from patients with myelodysplastic syndrome.
Topics: Acetylcysteine; Aged; Aged, 80 and over; Antioxidants; Blood Platelets; Chelating Agents; Deferipron | 2007 |
Oxidative stress in red blood cells, platelets and polymorphonuclear leukocytes from patients with myelodysplastic syndrome.
Topics: Acetylcysteine; Aged; Aged, 80 and over; Antioxidants; Blood Platelets; Chelating Agents; Deferipron | 2007 |
Oxidative stress in red blood cells, platelets and polymorphonuclear leukocytes from patients with myelodysplastic syndrome.
Topics: Acetylcysteine; Aged; Aged, 80 and over; Antioxidants; Blood Platelets; Chelating Agents; Deferipron | 2007 |
Recombinant human erythropoietin in the treatment of myelodysplastic syndromes--response patterns.
Topics: Aged; Aged, 80 and over; Anemia, Refractory; Anemia, Sideroblastic; Blood Transfusion; Chelation The | 1994 |
[Lymphocyte chemiluminescent activity under an iron overload of the body].
Topics: Antioxidants; Combined Modality Therapy; Deferoxamine; Dose-Response Relationship, Drug; Ferritins; | 1993 |
The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload.
Topics: Adolescent; Aged; Bone Marrow Diseases; Chromosome Aberrations; Deferoxamine; Erythropoietin; Female | 1996 |
[Long-term efficacy of subcutaneous administration of deferoxamine in patients with secondary hemochromatosis].
Topics: Aged; Anemia, Aplastic; Deferoxamine; Female; Hemochromatosis; Humans; Injections, Subcutaneous; Mal | 1996 |
[Therapy of transfusion hemochromatosis].
Topics: Blood Transfusion; Deferoxamine; Hemochromatosis; Humans; Injections, Subcutaneous; Myelodysplastic | 1997 |
Subcutaneous bolus injection of deferoxamine in adult patients affected by onco-hematologic diseases and iron overload.
Topics: Adult; Aged; Chelating Agents; Chelation Therapy; Deferoxamine; Female; Hematologic Diseases; Hemato | 1998 |
Desferrioxamine treatment reduces blood transfusion requirements in patients with myelodysplastic syndrome.
Topics: Adult; Aged; Blood Transfusion; Deferoxamine; Erythrocyte Indices; Humans; Leukocyte Count; Middle A | 1992 |
Deferoxamine-induced restoration of haematopoiesis in myelofibrosis secondary to myelodysplasia.
Topics: Aged; Deferoxamine; Hematopoiesis; Humans; Male; Myelodysplastic Syndromes; Primary Myelofibrosis | 1990 |